FDA Down to 5 Weeks of Funding to Review New Drug Applications
THURSDAY, Jan. 17, 2019 -- Due to the federal government shutdown, the U.S. Food and Drug Administration has only about five weeks of funding left to review new drug applications, according to Commissioner Scott Gottlieb, M.D.
To keep reviewing applications, the FDA has stretched those funds, which come from user fees paid by drug companies before the shutdown, Gottlieb said Monday on Twitter.
The FDA cannot accept new fees or applications until the shutdown is over, CNN reported. However, blood- and allergy-related products are not covered by the user fee program "so routine review activity ceased related to new products in these categories," Gottlieb said. He also said the FDA has about three months of funding for medical devices.
The partial shutdown began on Dec. 22 and on Jan. 12 became the longest government shutdown in U.S. history.
© 2020 HealthDay. All rights reserved.
Posted: January 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.